← Research library / Growth hormone axis

IGF-1 LR3: What the Evidence Actually Shows

Grade CNo US pathway

The risk here is immediate, not theoretical

IGF-1 has structural and functional overlap with insulin and can cause hypoglycaemia. Unlike most compounds in this library, where the concerns are long term and uncertain, this one has a plausible route to an acute medical emergency in the hours after administration.

The short version

A modified version of insulin-like growth factor 1 with an extended half life.
The LR3 modification reduces binding to carrier proteins, so more stays active for longer.
Raises IGF-1 directly rather than signalling the body to make it.
Carries real hypoglycaemia risk and unresolved questions about growth signalling.
No US approval and no pathway.

Why this is different from a secretagogue

Sermorelin and similar compounds ask the pituitary to release growth hormone, and the body's feedback loops still apply. IGF-1 LR3 bypasses all of that and supplies the downstream hormone directly, in a form specifically engineered to resist the binding proteins that normally regulate it. There is no natural brake.

The growth signalling question

IGF-1 is a growth signal. Elevated IGF-1 has been associated in epidemiological work with increased risk for certain cancers. Deliberately and substantially raising it, with an engineered molecule that evades normal regulation, is a meaningfully different proposition from restoring a youthful pulse pattern. Anyone with a personal or family cancer history should treat this as a hard no.

What this will not do

It will not behave like the body's own IGF-1. That is the entire design intent.
It will not be legally available.

Full library · Safety and sourcing · Reconstitution calculator · Compound index